Enveric (ENVB): Debts to Book Capitalization

Enveric Biosciences (ENVB) develops psilocybin-based psychopharmacological agents to combat anxiety. The share of debt financing in the balance sheet capitalization reflects a reduction in FDA regulatory risks. The AI-driven PsyAI platform accelerates the discovery of neuropsychiatric drugs, while a robust intellectual property portfolio ensures revenue from deals with industry behemoths. The value of 0.00 characterizes this level of financial leverage.

enveric.com (ENVB) - Debts to Book Value from 07/04/2022 to 10/27/2026

Metric breakdowns and analytics for Enveric Biosciences Inc (ENVB)

- price and consensus price forecast:

Price Chart Enveric Biosciences|ENVB - Fair Value Consensus

- market capitalization data:

Market Capitalization Enveric Corp|ENVB - Real Price to Acquire Entire Company

- book capitalization data:

Net Assets per Single Share Enveric Biosciences|ENVB - Total Stockholders' Equity|Market Cap to Net Assets Ratio enveric.com|ENVB - Aggregate Asset Value

- debt and liquidity data:

Total Debt to Capital Enveric Biosciences|ENVB - Long-Term Liabilities to Equity|Short-Term Debt to Capital Enveric|ENVB - Company Aggregate Debts|Debt to Book Capitalization Ratio Enveric Corp

Summary company analytics:ENVB, Enveric Biosciences

Manufactured product of Enveric Biosciences Inc

Enveric Biosciences (ENVB) demonstrates stable operational activity within a neutral biomedical sector. This total debt-to-equity ratio measures the degree of debt load relative to shareholders' equity. Low indicator values confirm solvency, whereas rising leverage signals insolvency risks. The humanitarian status of the products minimizes external threats, strengthening the financial foundation. This ensures price stability under any scenario.

Who Enveric Biosciences competes with